Market Intelligence: Myeloid Checkpoint Modulation (LILRB2/CD85d) & Mitochondrial Quality Control (ATAD1) in Immuno-Oncology.
Global Clinical Landscape & Future Outlook
The race for LILRB2/CD85d (myeloid immune checkpoint) and ATAD1 (synthetic lethality) therapeutics is intensifying. LILRB2 (CD85d, ILT4) is a key inhibitory receptor on myeloid cells, binding ligands such as HLA-G to suppress anti-tumor immunity. Major players (Merck, Immune-Onc, Agenus, Jounce) are advancing antagonist antibodies into Phase I/II trials for PD-1 refractory solid tumors. Concurrently, ATAD1 (Thorase), a mitochondrial AAA+ ATPase, is emerging as a synthetic lethal target in PTEN-deficient cancers. The convergence of myeloid checkpoint blockade and metabolic reprogramming via ATAD1 modulation represents the next frontier for overcoming immunotherapy resistance.
Key Functional Domains & Mutations (LILRB2): The extracellular region contains three Ig-like C2-type domains (UniProt Q8N423). Clinically relevant variants include dbSNP:rs383369, rs373032, and rs386056, which may impact ligand binding or immune regulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATAD1/LILRB2/CD85d drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (LILRB2) | LILRB2 (CD85d) ECD-Fc Fusion Protein: Extracellular domain (Met1–Glu443), Human IgG1 Fc, HEK293 expressed (native glycosylation), >95% purity, Endotoxin <1EU/μg, Sequence Verified | View LILRB2 Products |
| Antigen (ATAD1) | ATAD1 (Thorase) Recombinant Protein: Full-length AAA+ ATPase domain, Wild-type and E284Q mutant available, >95% purity, Theoretical MW verified | View ATAD1 Products |
| Ligand Protein | HLA-G Fc Fusion: Primary ligand for LILRB2; essential for blocking assays and affinity screening | View HLA-G Products |
| Gene Delivery | LILRB2 Lentivirus Premade Particles: Full-length ORF with GFP reporter, for stable monocytic cell lines (THP-1, U937) | View LILRB2 Products |
| Benchmark Ab | Anti-LILRB2 Reference Antibody (Biosimilar sequence): Recombinant positive control for assay standardization | View LILRB2 Products |
| Validator | LILRB2 siRNA Set (3 unique sequences): For knockdown verification and specificity checks | View LILRB2 Products |
| Related Target A | HLA-G: Primary ligand for LILRB2; crucial for ligand-blocking competition assays | View HLA-G Products |
| Related Target B | PTEN: Biomarker for ATAD1 synthetic lethality; bypass resistance pathways | View PTEN Products |
| Related Target C | LILRB1 (CD85j): For off-target liability screening within the LILR family | View LILRB1 Products |
| Related Target D | CSF1R (CD115): Synergistic myeloid checkpoint axis for combination therapy screening | View CSF1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity and theoretical MW verification; mass spectrometry validated |
| Subfamily counter-screening (LILRB family) | Homolog panel proteins (LILRB1-5) strictly verified by mass spectrometry and sequence analysis |
| HLA-G binding blockade verification | High-avidity LILRB2 ECD-Fc (native HEK293 glycosylation) for SPR/BLI competition assays with sub-nM precision |
| ATAD1 ATPase activity control | Wild-type ATAD1 and ATPase-dead (E284Q) mutant pair for functional validation and negative control in enzymatic assays |
| Lack of reliable controls | Clinical Benchmark Antibodies (Biosimilars) included with Endotoxin Controlled production |
| False positives in cell assays | Validated siRNA included for rigorous biological specificity checks |
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Merck, Immune-Onc, Agenus, Jounce | Solid Tumors (NSCLC, HNSCC, PD-1 refractory) | Ligand Blocking Assay (high-purity LILRB2 ECD-Fc and HLA-G) |
| Bispecific Antibody (LILRB2 x CSF1R/PD-1) | NGM Biopharmaceuticals, early-stage biotech | Macrophage-rich Tumors | Heterodimer Validation (cross-reactive ECD panels, strictly verified orthologs) |
| Small Molecule / PROTAC (ATAD1) | Academic / Emerging Pharma | PTEN-mutant Cancers (prostate, glioma) | Selectivity Assay (WT vs E284Q mutant proteins, Endotoxin <1EU/μg) |
| ADC (LILRB2-targeted) | Preclinical Biotech | Acute Myeloid Leukemia (AML) | Internalization Assay (full-length Lentivirus stable cell lines) |
Key Differentiation & Assay Strategies
For LILRB2/CD85d:
- Affinity & Epitope: Requires complete blockade of HLA-G binding without affecting LILRB1 (to avoid NK cell off-target toxicity). Use LILRB1/LILRB2 parallel proteins for cross-reactivity screening.
- Internalization: For ADC development, use LILRB2 lentivirus stable cell lines and pHrodo-labeled antibody uptake assays.
- Species Cross-Reactivity: Ortholog panels (human/cyno/mouse) validated by mass spectrometry for toxicology bridging.
For ATAD1:
- ATPase Activity: Wild-type and E284Q (ATPase-dead) mutant pair for functional gain/loss controls in HTS counter-screening.
- Selectivity: Ensure no off-target activity against other AAA+ ATPases via selectivity panel.
Live R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: